SCHEMBL315947

SCHEMBL315947

COC(=O)Cn1cnnn1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
HSD17B10 Q99714 3/20 0.51
ALOX15 P16050 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
ALOX12 P18054 1/20 0.46
RECQL P46063 1/20 0.46
HBB P68871 1/20 0.46
MAPT P10636 2/20 0.44
TP53 P04637 2/20 0.44
STAT5B P51692 1/20 0.44
HMOX1 P09601 1/20 0.44
LMNA P02545 1/20 0.43
ALPG P10696 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22118502 0.84 HSD17B10 (0.51) ALDH1A1HSD17B10ALOX15L3MBTL1MEN1
SCHEMBL10633527 0.83 HSD17B10 (0.61) ALDH1A1HSD17B10ALOX15L3MBTL1MEN1
SCHEMBL5206717 0.81 TP53 (0.56) ALDH1A1HSD17B10ALOX15MEN1KMT2A
SCHEMBL28046898 0.80 HSD17B10 (0.48) ALDH1A1HSD17B10ALOX15L3MBTL1MEN1
SCHEMBL16035137 0.79 HSD17B10 (0.47) ALDH1A1HSD17B10ALOX15L3MBTL1MEN1
SCHEMBL6629991 0.79 ALDH1A1 (0.44) ALDH1A1HSD17B10ALOX15L3MBTL1MEN1
SCHEMBL11676991 0.79 TP53 (0.41) ALDH1A1HSD17B10ALOX15L3MBTL1MEN1
SCHEMBL10633627 0.79 TP53 (0.50) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL22035923 0.78 ALDH1A1 (0.46) ALDH1A1HSD17B10ALOX15L3MBTL1MEN1
SCHEMBL48809 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556500-A1 SIMPLE ENZYMATIC PROCESS FOR PREPARING CEFAZOLIN Bioferma Murcia, S.A. (ES) 2005-07-27 EP claimed
WO-2004039997-A1 SIMPLE ENZYMATIC PROCESS FOR PREPARING CEFAZOLIN BIOFERMA MURCIA, S.A. (ES) 2004-05-13 WO claimed
EP-1416054-A1 Simple enzymatic process for preparing cefazolin Bioferma Murcia, S.A. (ES) 2004-05-06 EP claimed
CN-115397979-A Penicillin G acylase mutants with increased cefazolin productivity and uses thereof 艾美科健株式会社 2022-11-25 CN disclosed
WO-2021096298-A1 PENICILLIN G ACYLASE MUTANT HAVING INCREASED CEFAZOLINE PRODUCTIVITY AND USE THEREOF 아미코젠주식회사 2021-05-20 WO disclosed
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 US disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 US disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 US disclosed
WO-2004039997-A1 SIMPLE ENZYMATIC PROCESS FOR PREPARING CEFAZOLIN BIOFERMA MURCIA, S.A. (ES) 2004-05-13 WO disclosed
EP-1416054-A1 Simple enzymatic process for preparing cefazolin Bioferma Murcia, S.A. (ES) 2004-05-06 EP disclosed
US-4616024-A Dihydropyridine anti-ischaemic and antihypertensive agents PFIZER INC. (US) 1986-10-07 US disclosed
EP-0100189-B1 DIHYDROPYRIDINE ANTI-ISCHAEMIC AND ANTIHYPERTENSIVE AGENTS Pfizer Limited (GB) 1986-05-28 EP disclosed
US-4515799-A Dihydropyridine anti-ischaemic and antihypertensive agents PFIZER INC. (US) 1985-05-07 US disclosed
EP-0100189-A2 Dihydropyridine anti-ischaemic and antihypertensive agents Pfizer Limited (GB) 1984-02-08 EP disclosed
US-4314059-A Process for preparing cephalosporin compounds SHIBUYA CHISEI 1982-02-02 US disclosed
US-4258195-A Novel thiol esters and process for preparing cephalosporin compounds using same ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1981-03-24 US disclosed
EP-0004570-A1 Thiol esters, process for their preparation, pharmaceutical compositions containing them and a process for preparing cephalosporin compounds using the same Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1979-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317652-A1 Compounds Useful In Therapy AVPR1A, AVPR1B, AVPR2 ALDH1A1 2031/4885HSD17B10 2776/4885ALOX15 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.